伊立替康或多西他赛联合奥沙利铂治疗晚期非小细胞肺癌的临床观察

目的：观察伊立替康或多西他赛联合奥沙利铂治疗晚期非小细胞肺癌（NSCLC）的近期疗效及毒副作用。方法1晚期非小细胞肺癌68例中，伊立替康联合奥沙利铂组（A组）36例，采用伊立替康100mg／m2，第1、8天；奥沙利铂130mg／m2，第2天，静脉滴注。多西他赛联合奥沙利铂组（B组）32例，采用多西他赛75mg／m2，第1天；奥沙利铂130mg／m2，第2天，静脉滴注。21天为1周期，连用2周期后评定疗效。结果：A组和B组有效率分别为41．67％和31．25％，两组差异无统计学意义（P〉0．05）。A组迟发性腹泻和胆碱性综合征发生率明显高于B组（P〈0．01），但A组粒细胞减少发生率明显低于B组（P〈0．05）。结论：伊立替康或多西他赛联合奥沙利铂治疗晚期非小细胞肺癌有较好的疗效，不良反应可以耐受，安全性好，可以考虑作为晚期非小细胞肺癌治疗方案之一。

Clinical Study of Irinotecan or Docetaxe combined with Oxaliplatin on Patients with Advanced Non - small Cell Lung Cancer

Objective ：To observe and compare the recent objective response rate and adverse reaction of irinotecan or doeetaxe combined with oxaliplatin in the treatment of advanced non - small cell lung cancer （NSCLC）. Methods：68 patients with advanced NSCLC were divided into group A consisted of 36 patients re- ceived irinotecan plus oxaliplatin and group B consisted of 32 patients received doeetaxe plus oxaliplatin with a 21 - day regimen. Group A： irinoteean 100 mg/m2, day 1,8 ; oxaliplatin 130 mg/m/ , day 2. Group B ： doeetaxe 75 mg/m2 ,day 1 ;oxafiplatin 130 mg/m2 ,day 2. Two or more cycles of chemotherapy were completed in each group. Results：68 patients were assessable for efficacy and toxieities. The effective rate in group A was 41.67 % and in group B was 31.25%. The effective rate between the two groups had no significant difference （P 〉 0.05 ）. Group A had higher frequencies of delay diarrhoea and eholinergic syndrome（ P 〈 0.01 ）. The incidence of myelosuppression in group A was significantly lower than the group B （ P 〈 0.05 ）. Conclusions： Irinoteean combined with oxaliplatin is active in the treatment of advanced NSCLC, and the adverse reactions can be tolera- ted. It is a salvage regimen for advanced NSCLC.